Reuters logo
5 months ago
BRIEF-Aerie Pharmaceuticals announces resubmission of NDA for rhopressatm 0.02 pct
March 1, 2017 / 11:34 AM / 5 months ago

BRIEF-Aerie Pharmaceuticals announces resubmission of NDA for rhopressatm 0.02 pct

1 Min Read

March 1 (Reuters) - Aerie Pharmaceuticals Inc

* Aerie Pharmaceuticals announces resubmission of NDA for rhopressatm (netarsudil ophthalmic solution) 0.02 pct

* Aerie Pharmaceuticals Inc - pending approval, we anticipate product launch in Q2 of 2018 for rhopressa

* Aerie Pharmaceuticals - continue to expect in Q2 of 2017, readout of six-month safety and efficacy data for rhopressa Phase 3 registration trial

* Aerie Pharmac - anticipate in Q2'17, readout of 90-day efficacy data from mercury 2, Second Phase 3 registration trial for roclatan 0.02 pct/0.005 pct Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below